<?xml version="1.0" encoding="UTF-8"?>
<p id="Par53">Passive antibody administration through transfusion of immune (i.e. “convalescent”) plasma are often recommended as the sole short-term strategy to confer immediate immunity to susceptible ones. This approach has been used as post-exposure prophylaxis and/or treatment of contagious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, MERS etc.) [
 <xref ref-type="bibr" rid="CR102">102</xref>]. Though limited data suggested significant improvement [
 <xref ref-type="bibr" rid="CR103">103</xref>, 
 <xref ref-type="bibr" rid="CR104">104</xref>], however, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections and transfusion. Data from rigorously controlled clinical trials of convalescent plasma also are few [
 <xref ref-type="bibr" rid="CR102">102</xref>].
</p>
